Kalaris Therapeutics announces positive initial data from Phase 1a trial of TH103 for neovascular age-related macular degeneration (nAMD)
TH103 shows significant visual and anatomic improvements in treatment-naïve patients
The engineered properties of TH103 demonstrate potential for extended treatment durability
Mean 10-Letter Gain in Visual Acuity
TH103 showed a mean 10-letter improvement in best-corrected visual acuity after a single injection
Enhanced Intraocular Retention
TH103 exhibited 27 to 51-fold lower plasma Cmax compared to current leading agents, indicating increased intraocular retention
No Dose-Limiting Toxicities
TH103 was generally well tolerated with no dose-limiting toxicities or serious adverse events observed
- TH103's molecular design and preclinical profile supported by robust visual and anatomic improvements
- Positive results indicate potential for extended treatment durability with reduced systemic exposure
- Initial data suggests TH103's engineered properties may offer long-term benefits to nAMD patients
The promising Phase 1a data for TH103 support Kalaris Therapeutics' innovative approach in developing effective treatments for retinal diseases. With enhanced potency and intraocular retention, TH103 shows great potential for improving vision and patient outcomes in nAMD.